

Incarcerated Patients Living with HIV: Are We Appropriately Managing ASCVD Risk?

Sarah Michienzi, PharmD¹, Thomas Chiampas, PharmD^{1,2}, Amy Valkovec, PharmD Candidate¹, Siria Arzuaga, PharmD Candidate¹, Mahesh Patel, MD³, Scott Borgetti, MD³, Melissa Badowski, PharmD, MPH¹

1. University of Illinois at Chicago College of Pharmacy, Chicago IL; 2. Gilead Sciences Inc.; 3. University of Illinois at Chicago College of Medicine, Chicago IL

Introduction

- ❑ The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol included HIV as an ASCVD risk enhancer for the first time
- ❑ Providers may be delayed in incorporating new guideline recommendations into their practice

Methods

- ❑ Retrospective cohort from HIV Telemedicine Clinic
- ❑ Inclusion
 - Incarcerated in IDOC
 - ≥ 1 clinic visit during study period (1/1/19 - 6/1/19)
 - ≥ 18 years of age
 - HIV positive
- ❑ Exclusion
 - Existing ASCVD
- ❑ Primary Outcome
 - Appropriate statin use per 2018 ACC/AHA Guidelines


Disclosures

Dr. Chiampas is an employee of Gilead Sciences, Inc. At the time of this project, he was an employee of the University of Illinois at Chicago. The other authors have nothing to disclose in relation to this project or presentation.



AHA/ACC: American Heart Association/American College of Cardiology; ART: antiretroviral therapy (ABC: abacavir; INSTI: integrase strand transfer inhibitor; PI: protease inhibitor; TAF: tenofovir alafenamide; TDF: tenofovir disoproxil fumarate); ASCVD: atherosclerotic cardiovascular disease; FLP: fasting lipid panel (TC: total cholesterol; TG: triglycerides; HDL: high density lipoprotein; LDL: low density lipoprotein); HIV: human immunodeficiency disease; IDOC: Illinois Department of Corrections; SD: standard deviation; Statin: Hmg-CoA reductase inhibitor

Statin Appropriateness



35% of patients did not have a FLP in the past year
46% of patients with an FLP were not on appropriate statin therapy


Appropriate statin therapy for inmates with HIV is an area of improvement as we begin caring for an aging population.

Baseline Characteristics

Characteristics, n (%)*	N = 158
Age (years), mean ± SD	42 ± 12
Gender	
• Male	140 (89%)
• Female	10 (6%)
• Transgender Female	8 (5%)
Race	
• Black or African American	116 (73%)
• Hispanic / Latinx	13 (8%)
• White	9 (6%)
HIV Markers & History	
• CD4 Count > 200 cells/μL	153 (97%)
• Viral Load < 20 copies/mL	134 (85%)
• Years with HIV, mean ± SD	14 ± 9
ART Anchor Drug (N=152)	
• INSTI	131 (86)
• Multi-Class	10 (7)
• PI	6 (4)
• NNRTI	5 (3)
ART Backbone (N=152) [^]	
• TAF	109 (72)
• ABC	33 (22)
• TDF	4 (3)
• TAF + ABC	2 (1)


*Unless otherwise noted ^<100% because not on backbone of interest

Blood Cholesterol Levels



Median (Range) Lipids

10-Year ASCVD Risk



Median (Range) = 6.6%, (0.8% - 31.9%)

BMI Categorization

